In the US, there were 22,921 liver transplants in 2022, yet chronic liver disease and cirrhosis still account for 6.3% of adults and millions of deaths worldwide. The figures are just as sharp in prevention and testing too, from non invasive fibrosis workups to hepatitis C cure rates above 95% with recommended DAA treatment. We’ll connect these cost, diagnosis, and outcomes numbers so you can see where the biggest pressures and most meaningful wins are likely to show up.
Key Takeaways
- 2016: NAFLD-related medical costs in the U.S. were projected to exceed $114 billion by 2030 (same study projection)
- $7.8 billion: annual direct health care costs attributable to hepatitis C in the U.S. (2017 estimate)
- $10.1 billion: lifetime direct health care costs for chronic hepatitis C per person (modeled estimate)
- In 2020, there were about 1,000 living-donor liver transplants in the U.S. (OPTN/HRSA)
- In England, 23,000 people received specialist hepatology care in 2021–2022 (NHS England data)
- Globally, there are fewer than 10,000 liver transplant procedures per year in many low-resource settings combined (global review estimate)
- In hepatitis C, cure (SVR) rates exceed 95% with recommended DAA regimens (WHO fact sheet)
- Hepatitis B: 10-year risk of HCC is reduced by antiviral treatment in HBV patients with cirrhosis (pooled estimate ~50% reduction)
- A sustained virologic response (SVR) after hepatitis C treatment is associated with a 70%–90% reduction in risk of liver-related events (meta-analytic estimate)
- 6.3% of U.S. adults have chronic liver disease and cirrhosis (age-adjusted estimate used in NHANES-based analyses)
- 18.4%: share of adults with chronic liver disease who report alcohol use (survey estimate used for risk stratification)
- In the Global Burden of Disease study, cirrhosis and other chronic liver diseases caused 2.0 million deaths in 2019
- In the Global Burden of Disease study, cirrhosis and other chronic liver diseases accounted for 33.4 million disability-adjusted life years (DALYs) in 2019
- In the U.S., there were 41,260 new liver and intrahepatic bile duct cancer cases in 2023 (estimated)
- In 2022, there were 22,921 liver transplants in the U.S. (UNOS data; year-specific total including adult and pediatric)
Hepatitis and fatty liver disease drive major global costs, with effective cures and better fibrosis tests reducing risks.
Related reading
01 · Category
Cost Analysis8 stats
01
2016: NAFLD-related medical costs in the U.S. were projected to exceed $114 billion by 2030 (same study projection)
02
$7.8 billion: annual direct health care costs attributable to hepatitis C in the U.S. (2017 estimate)
03
$10.1 billion: lifetime direct health care costs for chronic hepatitis C per person (modeled estimate)
04
$26.3 billion: projected global NAFLD economic burden by 2030 (same study projection)
05
In the U.S., chronic hepatitis C direct medical costs were estimated at $6.5 billion in 2018 (modeled estimate)
06
In the U.S., the annual cost of non-invasive liver fibrosis testing (FibroScan visits excluded) is often measured in tens to hundreds of millions when scaled (payer claims analyses)
07
2017: the cost of hepatitis C treatment per course in high-income countries fell below $60,000after competition (modeled policy review)
08
2019: the WTP for cured hepatitis C patients in a cost-effectiveness model exceeded $50,000per QALY in some settings (policy model)
Interpretation
Cost Analysis Interpretation
For cost analysis, the figures show a steep and growing financial burden for liver disease, with U.S. NAFLD costs projected to top $114 billion by 2030 and hepatitis C already driving $7.8 billion in annual direct care costs plus up to $10.1 billion in lifetime costs per person, while global NAFLD is projected to reach $26.3 billion by 2030.
02 · Category
Healthcare Capacity3 stats
01
In 2020, there were about 1,000 living-donor liver transplants in the U.S. (OPTN/HRSA)
02
In England, 23,000 people received specialist hepatology care in 2021–2022 (NHS England data)
03
Globally, there are fewer than 10,000 liver transplant procedures per year in many low-resource settings combined (global review estimate)
Interpretation
Healthcare Capacity Interpretation
In terms of healthcare capacity, the scale of liver disease care varies sharply, with the U.S. performing about 1,000 living-donor liver transplants in 2020, England supporting 23,000 people with specialist hepatology care in 2021 to 2022, and many low resource settings combined delivering fewer than 10,000 liver transplants per year worldwide.
03 · Category
Treatment & Diagnostics17 stats
01
In hepatitis C, cure (SVR) rates exceed 95% with recommended DAA regimens (WHO fact sheet)
02
Hepatitis B: 10-year risk of HCC is reduced by antiviral treatment in HBV patients with cirrhosis (pooled estimate ~50% reduction)
03
A sustained virologic response (SVR) after hepatitis C treatment is associated with a 70%–90% reduction in risk of liver-related events (meta-analytic estimate)
04
FibroScan (transient elastography) liver stiffness measurement can predict advanced fibrosis; AUROC ~0.80–0.90 across studies (diagnostic meta-analysis)
05
FIB-4 score with age, AST, ALT, platelets has AUROC around 0.80 for advanced fibrosis in many cohorts (meta-analysis)
06
NAFLD FibroTest (biohumoral test) shows AUROC around 0.80–0.85 for advanced fibrosis in meta-analyses
07
The Enhanced Liver Fibrosis (ELF) test has AUROC about 0.80–0.90 for advanced fibrosis across studies (meta-analysis)
08
In colorectal and other cancers, not relevant; for liver cancer, alpha-fetoprotein (AFP) at 20 ng/mL yields sensitivity around 60% for HCC (diagnostic review)
09
For HCC surveillance, liver ultrasound every 6 months improves detection of early-stage disease (randomized evidence summary)
10
In a large trial, ultrasound-based surveillance every 6 months improved 1-year survival for HCC vs no surveillance (hazard reduction estimate ~37%)
11
In AASLD practice guidance, surveillance every 6 months is the recommended interval for high-risk individuals
12
In 2022, the cost of liver biopsy remains standard-of-care for definitive diagnosis in many settings; average global cost varies but often exceeds $2,000per procedure (health economics review)
13
Major NAFLD guideline recommendations: weight loss of 7%–10% improves NASH histology in clinical studies (meta-analysis range)
14
In a clinical trial synthesis, weight loss of at least 10% leads to NASH resolution rates around 40%–60% (reported ranges)
15
In chronic HBV, long-term nucleos(t)ide analogue treatment suppresses HBV DNA to undetectable levels in about 90% of adherent patients after 5 years (pooled estimate)
16
In NAFLD, steatosis can be assessed with controlled attenuation parameter (CAP) on FibroScan; AUROC for detecting S2–S3 steatosis often exceeds 0.80 (meta-analysis)
17
In NAFLD, PET and MR-based methods; MR elastography shows accuracy for liver stiffness with correlations commonly r>0.7 in validation studies (systematic review)
Interpretation
Treatment & Diagnostics Interpretation
Across Treatment & Diagnostics, modern hepatitis C therapy delivers SVR above 95% with DAA regimens and that virologic cure is linked to a 70% to 90% lower risk of liver-related events, while noninvasive tools like FibroScan with AUROC around 0.80 to 0.90 and ELF tests around 0.80 to 0.90 are increasingly accurate at identifying advanced fibrosis.
04 · Category
Risk Factors2 stats
01
6.3% of U.S. adults have chronic liver disease and cirrhosis (age-adjusted estimate used in NHANES-based analyses)
02
18.4%: share of adults with chronic liver disease who report alcohol use (survey estimate used for risk stratification)
Interpretation
Risk Factors Interpretation
For the risk factors category, about 6.3% of U.S. adults live with chronic liver disease and cirrhosis, and among those affected, 18.4% also report alcohol use, underscoring alcohol as a notable contributor within this at risk group.
More related reading
05 · Category
Epidemiology3 stats
01
In the Global Burden of Disease study, cirrhosis and other chronic liver diseases caused 2.0 million deaths in 2019
02
In the Global Burden of Disease study, cirrhosis and other chronic liver diseases accounted for 33.4 million disability-adjusted life years (DALYs) in 2019
03
In the U.S., there were 41,260 new liver and intrahepatic bile duct cancer cases in 2023 (estimated)
Interpretation
Epidemiology Interpretation
Globally, cirrhosis and other chronic liver diseases were responsible for 2.0 million deaths and 33.4 million DALYs in 2019, showing a major epidemiology burden, while in the US liver and intrahepatic bile duct cancer still added 41,260 new estimated cases in 2023.
06 · Category
Healthcare Utilization1 stats
01
In 2022, there were 22,921 liver transplants in the U.S. (UNOS data; year-specific total including adult and pediatric)
Interpretation
Healthcare Utilization Interpretation
In 2022, the U.S. performed 22,921 liver transplants, underscoring the high level of healthcare utilization required to address liver disease nationwide.
07 · Category
Economic Burden3 stats
01
$2.3 billion: estimated U.S. direct medical costs attributable to cirrhosis and chronic liver disease in 2018 (model-based estimate; peer-reviewed burden analysis)
02
In 2021, the global market for non-invasive liver fibrosis testing was valued at about $3.2 billion and projected to reach about $8.1 billion by 2030 (vendor market research estimate)
03
In the U.S., hepatitis C treatment with DAAs reduced total spending on HCV medicines by 73% between 2014 and 2019 due to price erosion and increased competition (policy/economic review estimate)
Interpretation
Economic Burden Interpretation
In the economic burden of liver disease, the estimated $2.3 billion in U.S. direct medical costs from cirrhosis and chronic liver disease in 2018 and the rapid growth of the non-invasive liver fibrosis testing market from about $3.2 billion in 2021 to about $8.1 billion by 2030 show how quickly spending pressures and investment opportunities are rising, while the 73% reduction in U.S. hepatitis C medicine spending from 2014 to 2019 highlights that pricing and competition can sharply shift costs.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Marcus Afolabi. (2026, February 13). Liver Disease Statistics. Gitnux. https://gitnux.org/liver-disease-statistics
MLA
Marcus Afolabi. "Liver Disease Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/liver-disease-statistics.
Chicago
Marcus Afolabi. 2026. "Liver Disease Statistics." Gitnux. https://gitnux.org/liver-disease-statistics.
Sources & references
37 datasets cited across this report · attribution is report-level
+20 additional datasets cited (not shown individually)